CD22 and neoplasm: In the present study, we generated a recombinant anti-CD22 scFv–apoptin fusion protein as a bifunctional molecule: the anti-CD22 scFv moiety targets the CD22 antigen on malignant B-cells surface and apoptin specifically kills the tumor cells.